Recommended Antimicrobial Therapy for Enterococcus casseliflavus Infection
For most E. casseliflavus infections, ampicillin is the first-line treatment, with ampicillin plus gentamicin combination therapy strongly recommended for serious infections including bacteremia and endocarditis.
Key Treatment Principles
E. casseliflavus carries intrinsic vancomycin resistance via the VanC gene, making vancomycin ineffective 1. This fundamentally changes the treatment approach compared to other enterococcal species.
Treatment by Infection Type
Bacteremia and Serious Systemic Infections
Ampicillin plus gentamicin is the preferred regimen for bloodstream infections and endocarditis 2, 3. Recent in vitro data demonstrates that this combination is:
- Synergistic against all E. casseliflavus isolates tested
- Bactericidal against all strains when ampicillin is dosed at 10 mg/L or higher 2
A critical clinical study found that anti-VRE agents (linezolid or daptomycin) resulted in significantly better outcomes than β-lactam monotherapy for vancomycin-resistant E. casseliflavus bacteremia, with treatment failure rates of 41.7% for β-lactam therapy versus improved outcomes with linezolid/daptomycin (adjusted risk ratio 1.73, p=0.031) 4. This suggests that when ampicillin plus gentamicin cannot be used, linezolid or daptomycin are superior alternatives to ampicillin alone.
Dosing for serious infections:
- Ampicillin: High-dose (18-30 g IV daily in divided doses) 5
- Gentamicin: Standard dosing with monitoring
- Duration: 6 weeks for endocarditis 3
Endocarditis
The successful treatment of aortic valve endocarditis with ampicillin plus gentamicin for 6 weeks combined with surgical valve replacement demonstrates this as the gold standard approach 3. The ampicillin/ceftriaxone combination, which works well for E. faecalis endocarditis, is NOT effective for E. casseliflavus - it showed synergy in only 1 of 10 E. gallinarum and 0 of 8 E. casseliflavus strains 2.
Uncomplicated Urinary Tract Infections
For simple UTIs, multiple effective options exist per guideline recommendations 5:
- Fosfomycin 3 g PO single dose (first choice for convenience)
- Nitrofurantoin 100 mg PO every 6 hours
- High-dose ampicillin (18-30 g IV daily) or amoxicillin 500 mg PO/IV every 8 hours
Intra-abdominal Infections
Tigecycline (100 mg IV loading dose, then 50 mg IV q12h) is recommended for intra-abdominal infections due to VRE, with treatment duration based on clinical response 5.
Complex/Refractory Infections
For polycystic liver infections or other difficult-to-treat sites 6:
- Initial therapy: Linezolid (600 mg IV/PO q12h) or meropenem plus linezolid
- Consider source control with drainage procedures
- Fluoroquinolones may be used for extended therapy (up to 48 days documented)
- PET-CT imaging may be necessary to identify occult infection sources
Critical Pitfalls to Avoid
Never use vancomycin - E. casseliflavus has intrinsic VanC-mediated resistance 1, 7
Avoid ampicillin/ceftriaxone combination - Unlike E. faecalis, this dual β-lactam regimen is not synergistic or bactericidal against E. casseliflavus 2
Do not use β-lactam monotherapy for serious infections - Clinical outcomes are significantly worse than combination therapy or anti-VRE agents 4
Gentamicin screening is not required - E. casseliflavus typically lacks high-level aminoglycoside resistance (none had gentamicin MIC >128 mg/L in recent studies) 2
Alternative Agents
When first-line therapy cannot be used:
- Linezolid 600 mg IV/PO q12h - Strong recommendation for enterococcal infections 5
- High-dose daptomycin 8-12 mg/kg IV daily - Can be combined with β-lactams for bacteremia 5
Antimicrobial Susceptibility Profile
E. casseliflavus is typically susceptible to 7:
- Ampicillin/penicillin (100%)
- Linezolid (100%)
- Gentamicin (100%)
- Nitrofurantoin (100%)
- Chloramphenicol (100%)
Resistance is common to lincomycin (99%) and quinupristin-dalfopristin (34%), with occasional resistance to fluoroquinolones (9.6%) 7.